Source The economics Times
MUMBAI — The long-awaited “patent cliff” for one of the world’s most lucrative drugs has finally arrived, triggering a massive rally in the Indian pharmaceutical sector. Shares of leading drugmakers jumped as much as 4% on Friday as the key patent for semaglutide—the active ingredient in Novo Nordisk’s blockbuster diabetes and weight-loss drugs, Ozempic and Wegovy—officially expired in India on March 20, 2026.
The Nifty Pharma index emerged as a top sectoral gainer, led by a flurry of activity from domestic giants preparing to flood the market with affordable generic versions.
The Market Reaction
Investors cheered the opening of a multi-billion dollar opportunity. Laurus Labs led the charge with a nearly 4% gain, while Sun Pharma, Dr. Reddy’s, Zydus Lifesciences, and Lupin saw their stocks climb between 2% and 3.5%.
Market analysts suggest the enthusiasm is well-founded. With the patent expiration, the Indian GLP-1 (glucagon-like peptide-1) market is projected to expand from its current 4-5% share of the diabetes segment to over 15-20% within the next 18 months.
A Price Revolution for Patients
For years, the high cost of innovator brands kept semaglutide out of reach for many. Novo Nordisk’s branded pens currently retail between ₹10,000 and ₹12,000 per month. However, the “generic wave” is expected to slash these prices by 50% to 80%.
Natco Pharma has already made waves by announcing a generic semaglutide injection starting at just ₹1,290 per month.
Sun Pharma and Zydus are preparing “Day 1” launches with indigenous delivery devices.
Industry experts predict monthly treatment costs will eventually stabilize between ₹3,000 and ₹5,000, making the “miracle drug” accessible to the middle-class population.
What Lies Ahead: Competition and Challenges
While the patent expiry is a win for affordability, the road ahead is expected to be “chaotic” as over 40 Indian firms prepare to launch more than 50 branded generics.
Manufacturing Scramble: Companies like Dr. Reddy’s are scaling up to produce millions of injectable pens, targeting not just India but other emerging markets where patents are also lapsing.
Delivery Innovation: To bypass secondary patents on Novo’s delivery pens, Indian firms have developed their own reusable and adjustable pen systems.
Regulatory Hurdles: With a sudden glut of products, medical experts warn of potential misuse for “lifestyle” weight loss and emphasize the need for strict prescription control to manage side effects.
“This represents more than just a commercial event; it’s a healthcare milestone for India,” said a senior analyst at CareEdge Ratings. “Early entrants who can establish trust through quality delivery systems will likely dominate this ₹5,000-crore opportunity.”
While the patent remains in force in the U.S. and Europe until the early 2030s, India has now become the primary battleground for the next generation of affordable metabolic medicine.
